Detalles de la búsqueda
1.
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
N Engl J Med
; 386(10): 942-950, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35263519
2.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 25(5): 626-635, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697156
3.
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Breast Cancer Res
; 26(1): 36, 2024 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38439079
4.
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
Cancer
; 130(2): 186-200, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37934000
5.
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours.
Br J Cancer
; 130(7): 1131-1140, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287179
6.
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Breast Cancer Res Treat
; 204(1): 123-132, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38019444
7.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308971
8.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36482193
9.
Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
Oncologist
; 27(3): 175-182, 2022 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274716
10.
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Br J Cancer
; 125(5): 679-686, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34158598
11.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34602290
12.
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results.
Cancer
; 126(11): 2597-2606, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32208524
13.
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Br J Cancer
; 123(11): 1590-1598, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32913286
14.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Nature
; 515(7528): 558-62, 2014 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25428503
15.
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Int J Cancer
; 145(7): 1798-1808, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30680712
16.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
Cancer
; 125(22): 3974-3984, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31318460
17.
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
Oncologist
; 24(12): e1409-e1416, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31420467
18.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717303
19.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 620, 2019 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31234810
20.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 517, 2019 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31146717